2022 Revenues ($USD) : $1,031,753,000
2022 R&D spend : $163,403,000
2022 Number of Employees : 2,003
Fiscal Year End : 3/31/2022
Company CEO : Michael Minogue, president and CEO

Abiomed develops circulatory and oxygenation support devices, including the Impella line of implants. Based in Danvers, Massachusetts, the company was founded in 1981 and has more than 2,000 full-time employees as of its most recent annual report, with more than half located in the U.S. The company was among the 10 best-performing medtech stocks in 2021 and has carried the momentum into 2022 with the first patient implants of its Impella 5.5 with SmartAssist in Japan, followed by the first Impella BTR heart pump implant in Chicago. Despite Street-beating results in its most recent fiscal quarter, Abiomed is scaling back expectations amid tough foreign exchange rates for U.S. companies. –SW